Study of the Effect of Adjunctive Vivomixx® in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis (SBP)

Spontaneous Bacterial Peritonitis Clinical Trial

Official title:

Study of the Effect of Adjunctive Vivomixx® in Addition to Antibiotics on Systemic and Cerebral Inflammatory Response in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis (SBP)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02552862
• Other study ID #: IIBSP-VSL-2014-49
• Status: Withdrawn
• Phase: Phase 3
• First received: August 26, 2015
• Last updated: December 14, 2016
• Start date: September 2016
• Est. completion date: December 2018

Study information

• Verified date: December 2016
• Source: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Comité Ético de Investigación Clínica
• Study type: Interventional

Clinical Trial Summary

Study Design: Double-blind placebo-controlled clinical trial

Study Duration:2 years

Study Center: Hospital de la Santa Creu i Sant Pau, Barcelona (single center)

Objectives: To assess the effect of adjunctive Vivomixx® on bacterial translocation in patients with cirrhosis and SBP

Number of Subjects: 30

Main Inclusion Criteria: Patients with cirrhosis hospitalized with an episode of SBP at Hospital de la Santa Creu i Sant Pau

Study Product, Dose, Route, Regimen: Vivomixx ® sachets containing 450 x 109 bacteria, 2 every 12 hours during hospitalization (n=15), or placebo (n=15)

Duration of administration: During hospitalization due to SBP episode

Hypothesis: The adjunctive treatment with Vivomixx® in patients with cirrhosis and SBP could decrease bacterial translocation and systemic and cerebral proinflammatory state. This would result in a faster SBP resolution, a decrease in the incidence of complications and an improvement in cognitive function.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2018
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with cirrhosis hospitalized with an episode of SBP at Hospital de la Santa Creu i Sant Pau.

Cirrhosis will be diagnosed by clinical, analytical and ultrasonographic findings or by liver biopsy. SBP will be diagnosed by an ascitic fluid neutrophil count > 250/mm3 with or without positive culture .

Exclusion Criteria:

• Advanced hepatocellular carcinoma (beyond Milan's criteria) or any other malignancy.

• Advanced liver insufficiency [MELD (model for end-stage liver disease) >25].

• Active alcohol intake (in the previous 3 months).

• Neurological disease.

• Marked symptomatic comorbidities (cardiac, pulmonary, renal, untreated active depression, HIV infection).

• Previous antibiotic treatment, including norfloxacin and rifaximin.

• Septic shock, ileus, need for tracheal intubation or intensive care unit.

• Immunomodulatory drugs.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Peritonitis
• Spontaneous Bacterial Peritonitis

Intervention

Drug:
• Vivomixx®
Vivomixx® is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) and lactobacilli (L. paracasei DSM 24733, L. acidophilus DSM 24735, L. delbrueckii subsp bulgaricus DSM 24734, L. plantarum DSM 24730). The active agent will be supplied as a 4.4g sachet at a dose of 450 billion live bacteria per sachet with maltose and silicon dioxide as excipients.
• Placebo
Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.

Locations

Country	Name	City	State
Spain	Hospital de la Santa Creu i Sant Pau	Barcelona

Sponsors (1)

Lead Sponsor	Collaborator
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in bacterial translocation (composite measure)	Bacterial translocation will be evaluated by change from baseline in bacterial DNA in blood and ascitic fluid, lipopolysaccharide binding protein (LBP), intestinal fatty acid-binding protein (I-FABP) and intestinal bile acid binding protein (I-BABP) in blood, and polyethylene glycols (PEG) and claudin 3 in urine .	At baseline, daily until infection resolution (an expected average of 7 days) and at three months after discharge	Yes
Secondary	Changes in systemic inflammatory response and systemic oxidative damage (composite measure)	Systemic Inflammation and immune response will be evaluated by change from baseline in serum C reactive protein (CRP), interleukin (IL)-1ß, IL-6, tumor necrosis factor (TNF)-a, IL-10, IL-12, IL-18, IL-22, sTNFR-1, sTNFR-2, sCD163, matrix metalloproteinase (MMP) -9, interferon (IFN)-?, vascular endothelial growth factor (VEGF), claudin-5, nitrites and nitrates in serum and ascitic fluid.; Systemic oxidative damage will be evaluated by change from baseline in determination of malondialdehyde (MDA) in blood.	At baseline, daily until infection resolution (an expected average of 7 days) and at three months after discharge	Yes
Secondary	Changes in cognitive function (composite measure)	Cognitive function will be evaluated by change from baseline in Trail-Making Test A (TMT-A), Trail-Making Test B (TMT-B), and Digit Symbol Test (DST).	At baseline at infection resolution (an expected average of 7 days)	Yes
Secondary	Changes in brain inflammation (composite measure)	Brain inflammation will be evaluated by change from baseline in MRI and different biomarkers of neuroinflammation.; A designed MR protocol will be produced, including imaging using different sequences, and more biochemical (MR spectroscopy) and functional (DTI) studies.	At baseline (during the first 12-24 hours after inclusion in the study) and after 3 days of treatment.	Yes